Aptinyx

Evanston
Illinois
United States

Show jobs for this employer

62 articles with Aptinyx

  • Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2020 and highlighted recent progress across the company’s clinical-stage pipeline of novel NMDA receptor modulators.

  • Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management is scheduled to participate in two upcoming investor conferences

  • Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, November 12, 2020 at 5:00 p.m. ET to report third quarter 2020 financial results and discuss recent business highlights. To access the live conference call, please

  • Aptinyx Inc. announced the closing of its public offering of 16,100,000 shares of its common stock, which included the exercise in full of the underwriters’ option to purchase additional shares, at a public offering price of $3.00 per share.

  • It was another busy week for clinical trial updates and news. Here’s a look.
  • Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, announced the pricing of its public offering of 14,000,000 shares of its common stock at a public offering price of $3.00 per share.

  • Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it intends to offer and sell 12,000,000 shares of its common stock in an underwritten public offering

  • Shares of Aptinyx skyrocketed more than 75% after the company reported its mid-stage experimental treatment for post-traumatic stress disorder demonstrated clinically meaningful and statistically significant results that will set up a pivotal study next year.
  • Clinically meaningful and statistically significant improvement on CAPS-5 Arousal and Reactivity Score observed with NYX-783 Clinically meaningful improvement from baseline on CAPS-5 Total Score observed in 50 mg dose arm Statistically significant separation of 50 mg from placebo achieved on multiple measures of responder rate on CAPS-5 Total Score Observed safety and tolerability similar to placebo Data support discussion with FD

  • Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has re-activated study sites and recommenced patient recruitment in a Phase 2 study of NYX-2925 in patients with fibromyalgia.

  • Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, announced that company management will be presenting at the following virtual investor conferences:

  • Completed enrollment in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in 4Q 2020 Recommencement of Phase 2 studies of NYX-2925 in chronic pain expected soon Conference call today at 5:00 p.m. ET EVANSTON, Ill.--( BUSINESS WIRE )-- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financi

  • Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will be presenting at the 2020 Wedbush PacGrow Healthcare Virtual Conference. The presentation will take place on Tuesday, August 11, 2020 at 2:20 PM EDT. A live webcast of each presentation will be available on the

  • Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 13, 2020 at 5:00 p.m. ET to report second quarter 2020 financial results and discuss recent business highlights.

  • Aptinyx to Host PTSD-Focused R&D Day on August 5 th , 2020 Program to feature presentation from Dr. Murray Stein, Distinguished Professor of Psychiatry at UCSD and board-certified psychiatrist Aptinyx expects data from exploratory Phase 2 study of NYX-783 in PTSD in late 2020 EVANSTON, Ill.--( BUSINESS WIRE )-- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of bra

  • Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, will be added as a member of the US small-cap Russell 2000® Index. The addition will be effective after the US market opens on June 29, 2020 as part of the 2020 Russell US Indexes annual reconstitution. Inclusion in the Russell 2000® Index, which remains

  • Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the completion of enrollment in its ongoing Phase 2 exploratory study of NYX-783 to evaluate the safety and efficacy of NYX-783 in patients with post-traumatic stress disorder (PTSD). The company anticipates reporting data from the study in late 2020. “The completi

  • Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will be presenting at the following upcoming investor conferences: 2020 BMO Prescription for Success Healthcare Conference on Tuesday, June 23, 2020 at 2:30 p.m. ET and; SVB Leerink CybeRx Series: 2 nd Annual CNS Forum on Wednesda

  • Over 90% of target enrollment achieved to date in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in late 2020

  • Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, May 14, 2020 at 5:00 p.m. ET to report first quarter 2020 financial results and discuss recent business highlights. To access the live conference call, please dial 1-866-930-5579 (domestic)